학술논문

Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.
Document Type
article
Source
Nature. 413(6857)
Subject
PC12 Cells
Animals
Animals
Genetically Modified
Rats
Drosophila
Huntington Disease
Neurodegenerative Diseases
Disease Models
Animal
Nerve Degeneration
Histone Deacetylases
Acetyltransferases
Glutathione Transferase
Glutamine
Peptides
Trans-Activators
Saccharomyces cerevisiae Proteins
Drosophila Proteins
Nerve Tissue Proteins
Nuclear Proteins
Histones
Repressor Proteins
Enzyme Inhibitors
Gene Expression Regulation
Repetitive Sequences
Amino Acid
Protein Structure
Tertiary
Acetylation
E1A-Associated p300 Protein
CREB-Binding Protein
Histone Acetyltransferases
Sin3 Histone Deacetylase and Corepressor Complex
Histone Deacetylase Inhibitors
Huntingtin Protein
Neurodegenerative
Neurosciences
Genetics
Brain Disorders
Huntington's Disease
Rare Diseases
Aetiology
2.1 Biological and endogenous factors
Neurological
General Science & Technology
Language
Abstract
Proteins with expanded polyglutamine repeats cause Huntington's disease and other neurodegenerative diseases. Transcriptional dysregulation and loss of function of transcriptional co-activator proteins have been implicated in the pathogenesis of these diseases. Huntington's disease is caused by expansion of a repeated sequence of the amino acid glutamine in the abnormal protein huntingtin (Htt). Here we show that the polyglutamine-containing domain of Htt, Htt exon 1 protein (Httex1p), directly binds the acetyltransferase domains of two distinct proteins: CREB-binding protein (CBP) and p300/CBP-associated factor (P/CAF). In cell-free assays, Httex1p also inhibits the acetyltransferase activity of at least three enzymes: p300, P/CAF and CBP. Expression of Httex1p in cultured cells reduces the level of the acetylated histones H3 and H4, and this reduction can be reversed by administering inhibitors of histone deacetylase (HDAC). In vivo, HDAC inhibitors arrest ongoing progressive neuronal degeneration induced by polyglutamine repeat expansion, and they reduce lethality in two Drosophila models of polyglutamine disease. These findings raise the possibility that therapy with HDAC inhibitors may slow or prevent the progressive neurodegeneration seen in Huntington's disease and other polyglutamine-repeat diseases, even after the onset of symptoms.